National Institute of Neurological Disorders and Stroke (NINDS)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Institute of Neurological Disorders and Stroke (NINDS) sits in the top decile of US sponsors by registered trial count (#61 of 15,742 sponsors by registered trial count).
National Institute of Neurological Disorders and Stroke (NINDS): 567 sponsored US clinical trials, 48 recruiting.
National Institute of Neurological Disorders and Stroke (NINDS) sponsors 567 registered US clinical trials on ClinicalTrials.gov, 48 of them currently recruiting, and 467 completed. 16 of these trials are in Phase 3-4 (later-stage) and 158 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 23 trials.
Top-decile sponsor footprint
National Institute of Neurological Disorders and Stroke (NINDS) ranks in the top decile of sponsors by registered trial count (#61 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
467 of 508 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
567 total, page 12 of 12
Intravenous Immunoglobulin (IVIg) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT00001287
Intravenousimmunoglobulin (IVIg) for the Treatment of Inflammatory Myopathies
NCT00001261
Effect of Estrogen on Mental and Social Functioning in Girls With Turner's Syndrome
NCT00004274
Genetic Studies in Alzheimer's Disease
NCT00001235
Gene Therapy for Gaucher's and Fabry Disease Using Viruses and Blood-Forming Cells
NCT00001234
Non-Invasive Electrical Stimulation of the Human Brain
NCT00001216
Evaluation of Neuromuscular Disease
NCT00001201
Study of "Post-Polio Syndrome"
NCT00001185
Brain Study of Patients With Frontal Lobe Dementia and Parkinsonian Disorders
NCT00001178
Evaluation of Factors in Human Brain Tumors
NCT00001171
Assessment of Patients With Multiple Sclerosis (MS)
NCT00001156
Monitoring Patients With Uncontrolled Epilepsy
NCT00001149
Hormone Replacement in Menopausal Women With Epilepsy
NCT00027209
Families In Recovery From Stroke Trial (F.I.R.S.T.)
NCT00037492
Treatment of AIDS Vacuolar Myelopathy With Methionine
NCT00032695
Antiplatelet Therapy to Prevent Stroke in African Americans
NCT00004727
Aspirin Or Warfarin To Prevent Stroke
NCT00004728
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 80 |
| Phase 2 | 78 |
| Phase 3 | 11 |
| Phase 4 | 5 |
Therapeutic Areas
What is open in the National Institute of Neurological Disorders and Stroke (NINDS) pipeline
48 recruiting of 567 indexed (8% open); 467 completed (82%).
Phase mix: 16 late (III/IV) vs 158 early (I/II) (early-phase heavy).
Top condition: Healthy (23 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
National Institute of Neurological Disorders and Stroke (NINDS): open-pipeline peers nationwide
Peers matched on 567 registered trials and 8% open enrollment, not the therapeutic-area sidebar.
National Institute of Neurological Disorders and Stroke (NINDS) sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 567 trials (± recruiting share)
- Children's Hospital Medical Center, Cincinnati · 571 trials · 19% recruiting
- University of Maryland, Baltimore · 560 trials · 18% recruiting
- Amgen · 558 trials · 10% recruiting
- Merck Sharp & Dohme · 558 trials · 22% recruiting
Sponsors near 8% open enrollment (± trial volume)
- National Jewish Health · 8% recruiting · 83 trials
- ACADIA Pharmaceuticals · 9% recruiting · 35 trials
- Texas Tech University Health Sciences Center, El Paso · 9% recruiting · 35 trials
- Boehringer Ingelheim · 8% recruiting · 515 trials
Related
What to do with this National Institute of Neurological Disorders and Stroke (NINDS) page
567 registered trials is a research-attention snapshot, not an endorsement of National Institute of Neurological Disorders and Stroke (NINDS) or any single study.
- 48 of National Institute of Neurological Disorders and Stroke (NINDS)'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Healthy is the condition National Institute of Neurological Disorders and Stroke (NINDS) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. National Institute of Neurological Disorders and Stroke (NINDS) pipeline card: 567 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.